Further, many of the inhibited upstream regulators identified (Tables 3 and 5) have strong pro-tumor activities (e.g., TGFB1, which increases glioma malignancy [49]), consistent with the overall strong anti-tumor responses that we have seen in the metronomic CPA-treated gliomas. Here, TGFB1 is linked to central nervous system cancer.